GlassScriptPhysician profile
Katherine C Haney
NPI 1902809098
$5,316.03
in general payments reported to CMS, 2019-2025
33 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $175 · 2021: $3,155 · 2022: $679 · 2023: $400 · 2024: $237 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $2,500.00 | 2021 | |
| Abbvie INC. | $429.64 | 2019-2023 | |
| Aspira Women'S Health INC | $275.19 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $219.19 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $216.16 | 2023-2025 | Myfembree, Gemtesa |
| Hologic Sales and Service, LLC | $189.06 | 2020-2025 | Unifi Workspace, 3dimensions, Thinprep 2000 Processor |
| Astellas Pharma US INC | $158.35 | 2019-2025 | Veozah, Myrbetriq |
| Millicent US INC | $147.16 | 2021-2024 | Intrarosa, Femring |
| Mayne Pharma Commercial LLC | $133.89 | 2022-2025 | |
| Pfizer INC. | $117.27 | 2019-2022 | |
| Avion Pharmaceuticals | $107.42 | 2020-2023 | Balcoltra |
| Coopersurgical, INC. | $104.53 | 2019-2025 | Endosee |
| Channel Medsystems, INC. | $95.82 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.73 | 2019-2025 | |
| Daiichi Sankyo INC. | $69.91 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39.75 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $39.59 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $39.24 | 2019 | |
| Shield Therapeutics INC | $39.08 | 2022-2023 | Accrufer |
| Lupin INC. | $37.38 | 2019 | |
| Therapeuticsmd, INC. | $33.09 | 2022 | |
| Medtronic, INC. | $33.02 | 2023 | Mazor X System |
| Exeltis, USA INC. | $30.61 | 2020-2021 | |
| Myovant Sciences INC. | $30.29 | 2021-2022 | |
| Allergan, INC. | $23.83 | 2019 | |
| Novo Nordisk INC | $23.29 | 2023 | Rybelsus, Ozempic |
| Biogen, INC. | $19.07 | 2024 | |
| Currax Pharmaceuticals LLC | $16.50 | 2023 | Contrave |
| Minerva Surgical, INC | $14.73 | 2019 | |
| Agile Therapeutics, INC. | $14.02 | 2021 | |
| Vertical Pharmaceuticals, LLC | $13.59 | 2019 | |
| Boston Scientific Corporation | $13.20 | 2020 | |
| Evofem Biosciences, INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Haney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.